This is supported by the fact that some of the genes and pathways identified in our analysis are associated with biomarkers currently used in the clinic, as is the case with MUC16 for gynecological cancers or CA19-9 (sialyl LewisA, a fucosylated antigen) for gastro-intestinal cancers.2 Here, MUC16 is linked to female reproductive organ cancer.